A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.
Nuria Kotecki(Centre Oscar Lambret), Naimish Pandya(Integrated BioTherapeutics (United States)), B. Dekeyser(Antwerp University Hospital), Samuel L. Murphy(Integrated BioTherapeutics (United States)), Vladimir Galvao(Hebron University), Hans Prenen(Province of Antwerp), Jonathan P. McNally(Integrated BioTherapeutics (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Sylvie Rottey(Ghent University Hospital), Brant Delafontaine(Ghent University Hospital), Omar Saavedra(Hospital Quirónsalud Barcelona), A. Drumheller(Integrated BioTherapeutics (United States)), Jijun Dong(Integrated BioTherapeutics (United States)), Jennifer Lindelien(Integrated BioTherapeutics (United States)), Valentina Boni
Cited by 0
Related Papers
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
|JAMA Oncology|2018|315
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations
|Journal of Clinical Oncology|2021|196